核医学诊疗一体化在分化型甲状腺癌术后评估中的应用  

Nuclear medicine theranostics for the management of differentiated thyroid carcinoma

作　　者：张英杰 林岩松 ZHANG Yingjie;LIN Yansong(Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences,Jinan 250071;Department of Nuclear Medicine,Peking Union Medical College Hospital,Peking Union Medical College&Chinese Academy of Medical Sciences,Beijing 100730,China)

机构地区：[1]山东第一医科大学附属肿瘤医院核医学科(山东省肿瘤防治研究院,山东省肿瘤医院),山东济南250071 [2]中国医学科学院、北京协和医学院北京协和医院核医学科,北京100730

出　　处：《西安交通大学学报（医学版）》2024年第1期15-22,共8页Journal of Xi’an Jiaotong University（Medical Sciences）

基　　金：国家重点研发计划“政府间国际科技创新合作/港澳台科技创新合作”重点专项(No.2019YFE0106400);中央高水平医院临床科研业务费资助(No.2022-PUMCH-B-072);国家自然科学基金项目(No.81771875);山东省自然科学基金项目(No.ZR2019PH051)。

摘　　要：分化型甲状腺癌(DTC)因其发病率逐年增高而引人关注,伴随着核医学诊疗一体化手段的不断完善以及分子生物学等技术在DTC中的深入研究,有关其诊断及治疗理念也在不断更新。本文结合现有的诊疗一体化实践以及循证医学证据和相关指南推荐,对131 I治疗前评估体系进行系统阐述。With the increase of its incidence,differentiated thyroid carcinoma(DTC)has become a global concern.Over the recent decades,the guidelines for the management of DTC have been kept updating along with the development of nuclear medicine theranostics and molecular biology.The present article will systematically expound on the 131 I pre-treatment evaluation system based on the clinical practice of nuclear medicine theranostics,the latest evidence-based medical evidence,and guideline recommendations.

关 键 词：甲状腺肿瘤 核医学 诊疗一体化 

分 类 号：R736.1[医药卫生—肿瘤] R817.8[医药卫生—临床医学]